Fund dismisses fears of AI reducing drug development spending, citing Medpace’s $13.57 billion market cap and 59% annual gain.
Madison Small Cap Fund increased its position in Medpace Holdings (MEDP) during Q1 2026, countering concerns over AI disruption in drug development. The fund argued fears of reduced spending are overstated, predicting AI tools will instead boost demand for clinical research services.
Medpace shares rose 14.4% over the past month and 59.3% in the last 52 weeks, closing at $475.07 on June 11, 2026. The company’s market capitalization stands at $13.57 billion. The fund highlighted Medpace’s resources to implement AI, potentially improving trial timelines and submissions.
Healthcare was the fund’s worst-performing sector in Q1, with holdings like Charles River Labs (CRL) also pulling back due to AI-related volatility.